The early colorectal cancer test will be developed using Tagomics’ Interlace platform for identifying DNA-based biomarkers.

An ongoing clinical trial called "BREAKWATER" is showing great promise for metastatic colon cancer patients with a particular ...

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860 k Innovate ...

Cambridge biomarker discovery and diagnostics company Tagomics has been awarded £860k Innovate UK funding as it steps up its ...

The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

Scientists have discovered a range of "biomarkers" that could help to improve detection and treatment of gastrointestinal ...

Certain GI disorders share microbial biomarkers, with researchers predicting this could lead to new diagnostic tools for ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...